title: Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.
abstract: TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing research regarding immunomodulators, new promising insights have been developed that can contribute in the control of TB. This is the case of antimicrobial peptides, which can be potential therapeutic or adjuvant agents. The current high cost of antimicrobial peptide synthesis may be a current deterrent for treatment; antimicrobial peptide-inducers can be an alternative for low-cost treatment and/or adjuvants.
authors.affiliation: Rutgers University School of Public Health, Department of Environmental & Occupational Health, Center for Global Public Health, Piscataway, NJ, USA.
authors.forename: Cesar Enrique
authors.initials: CE
authors.lastname: Rivas-Santiago
authors.forename: Rogelio
authors.initials: R
authors.lastname: Hernández-Pando
authors.forename: Bruno
authors.initials: B
authors.lastname: Rivas-Santiago
mesh_terms: D023181:Antimicrobial Cationic Peptides / Q000235:genetics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D007113:Immunity, Innate; D056747:Immunomodulation; D007167:Immunotherapy / Q000191:economics / Q000379:methods*; D007532:Isoleucine / Q000378:metabolism / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000276:immunology* / Q000628:therapy*; D015854:Up-Regulation; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D023181:Antimicrobial Cationic Peptides; D007532:Isoleucine; D014807:Vitamin D